
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Pharma Faceoff is a video program bringing together key opinion leaders from across the healthcare and pharmaceutical industry to debate the key issues of the day
Pharma Faceoff is a video program bringing together key opinion leaders from across the healthcare and pharmaceutical industry to debate the key issues of the day






